Catenae Innovation PLC (LON:CTEA) said it has begun trialling and finalising its Cov-ID app for tracking coronavirus (COVID-19) contact. On May 1, the group announced it had created an operational prototype of the GDPR-compliant identity documentation exchange system. Catenae is working with a consortium of companies led by the Z/Yen Group to develop a product that will be marketed to businesses and “other organisations”.
Open Orphan PLC (LON:ORPH) has confirmed that its coronavirus COVID-19 Antibody Microarray machine is on-site at hVivo’s laboratory in east London and is undergoing testing. The move follows the company’s tie-up with Quotient Limited, announced recently. The machine, which will be fully operational in two weeks, can carry out 3,000 tests per day. In Monday’s update, Open Orphan also said it is in discussions with channel partners to secure new business.
e-Therapeutics PLC (LON:ETX) shares rose on Monday as the firm said it has begun experimental testing on the first set of compounds for the treatment of coronavirus (COVID-19) identified using its proprietary network-driven drug discovery (NDD) platform. The AIM-listed firm said the initial compound set, which it believes has the potential to address both viral replication and the associated excessive immune response, will be tested by WuXi AppTec utilising its relevant cell-based assays.
Separately, e-therapeutics also clarified arrangements for its upcoming annual general meeting that is still to be held at 11.00am on June 2, 2020. It said that in response to the current coronavirus (COVID-19) pandemic and stay at home measures in place, the 2020 AGM will now be held at 17 Blenheim Office Park, Long Hanborough, Oxfordshire OX29 8LN (which is the Company’s registered office) and not at the offices of Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH.
Conroy Gold and Natural Resources PLC (LON:CGNR) has identified new geological and structural features on the Clontibret gold project which it says are important in regard to controls on high gold grades within the deposit. The geophysical survey centred on the Clontibret gold target area where the company proposes to develop its first gold mine. The Clontibret target is one of a series of gold targets on the 65 kilometre district-scale gold trend that the company has discovered, and has been granted licences over, in the Longford-Down Massif in Ireland.
OptioBiotix Health PLC (LON:OPTI) said its revenues in the first three months of the year rose by 928% year-on-year boosted by its partnership agreements. The total invoiced sales of its LPLDL and SlimBiome offerings as ingredients or final product were £407,844, compared to £39,645 in the same period of 2019. On top of those revenues, the company, which is focused on developing compounds to tackle obesity, cardiovascular disease and diabetes, also received proceeds of £162,500 of investment income from the disposal of shares in SkinBioTherapeutics…